Skin Disorders News

Topical tapinarof cream showed significant improvement of moderate to severe atopic dermatitis while being well tolerated by adults and children down to age 2 years, according to two phase 3 clinical trials.

Due to a small increase in eczematous dermatitis, older adults taking antihypertensive drugs should be monitored and this possibility considered when assessing for eczema, according to a study.

Johnson & Johnson will pay $850 million to acquire the biotechnology company Proteologix Inc., the company announced in a press release.

Patients with hereditary angioedema experienced fewer hospitalizations and ED and outpatient visits after beginning prophylactic treatment with berotralstat, according to a poster presented at a recent conference.

Arcutis Biotherapeutics reported Zoryve net sales of $21.6 million in the first quarter of 2024, the company announced in a press release.

Ruxolitinib cream 1.5% was safe and well tolerated up for the short- and long-term treatment of atopic dermatitis in adolescents, according to an analysis of two phase 3 studies.

Galderma has received filing acceptances for nemolizumab for the treatment of prurigo nodularis and atopic dermatitis in Australia, Singapore, Switzerland and the United Kingdom, the company announced in a press release.

Technoderma Medicines has dosed its first patients in its phase 2a clinical trial of topical TDM-180935 ointment for the treatment of atopic dermatitis, the company announced in a press release.

Eli Lilly and Company announced a net revenue increase of 26% in the first quarter of 2024 and the resubmission of its biologic license application for lebrikizumab for the treatment of atopic dermatitis, according to a press release.

SelectION announced positive results from its first-in-human phase 1b trial of its lead compound, a selectively-optimized peptide, for the treatment of patients with atopic dermatitis, according to a company press release.